New combo therapy aims to boost survival in hard-to-treat head and neck cancer
NCT ID NCT06790966
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This phase 3 study tests whether adding an experimental immunotherapy (PDS0101) to standard pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer or delay tumor growth. About 252 adults whose cancer has spread or returned and cannot be removed by surgery will be randomly assigned to receive either the combination or pembrolizumab alone. The goal is to see if the combination improves overall survival and progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University - Winship Cancer Institute (WCI)
Atlanta, Georgia, 30322, United States
-
Florida Cancer Affiliates - Ocala Oncology
Ocala, Florida, 34474, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19103, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Marin Cancer Care
Greenbrae, California, 94904, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29407, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Penn State Health
Hershey, Pennsylvania, 17033, United States
-
SCRI - Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Texas Oncology
Austin, Texas, 78705, United States
-
Texas Oncology-Northeast Texas
Tyler, Texas, 75702, United States
-
The Ohio State University- James Cancer Hospital
Columbus, Ohio, 43210, United States
-
UT Health San Antonio
San Antonio, Texas, 78229, United States
-
University of California, Orange
Orange, California, 92686, United States
-
University of Kansas
Westwood, Kansas, 66205, United States
-
University of Kentucky
Lexington, Kentucky, 40536, United States
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599-7025, United States
-
University of Tennessee Medical Center
Knoxville, Tennessee, 37920, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22903, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
West Virginia University Cancer Center
Morgantown, West Virginia, 26506, United States
-
Yale University
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.